person · Reporting owner
Ploos van Amstel Arnout
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zura Bio LtdZURA · Entity 5413 | Director | May 21, 2025 | May 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zura Bio Ltd
Report date May 21, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2035-05-21 | Direct | 51,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 51,000 · Balance 51,000 F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2025 Filed May 22, 2025 21:39 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001415889-25-014227 · form4-05222025_090523.xml · derivative · entry 1 Ploos van Amstel Arnout · CIK 0001870330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:45 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028977 · form4-12112024_041213.xml · derivative · entry 1 Ploos van Amstel Arnout · CIK 0001870330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Class A Ordinary Shares · 117,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| May 17, 2024 Filed May 23, 2024 12:53 UTC | Zura Bio Ltd ZURA · Entity 5413 | PurchaseClass A ordinary shares | 80,000 | $6.20 | $496,000.00 |
DisclosureSEC source: 0001415889-24-014179 · form4-05232024_120531.xml · nonDerivative · entry 1 Ploos van Amstel Arnout · CIK 0001870330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $6.194848 to $6.199696 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:32 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantStock options · Derivative | 48,149 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001104659-24-007065 · tm244212-3_4seq1.xml · derivative · entry 1 Ploos van Amstel Arnout · CIK 0001870330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,149 Underlying: Class A Ordinary Shares · 48,149 shares Expires 2034-01-24 F1 · shares: Consists of options to purchase 48,149 Class A Ordinary Shares. The vesting for 48,149 shares began on November 9, 2023 and would vest over a period of three years, with each 1/3 on an annual basis. F1 · derivative.exercise_date: Consists of options to purchase 48,149 Class A Ordinary Shares. The vesting for 48,149 shares began on November 9, 2023 and would vest over a period of three years, with each 1/3 on an annual basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.